Ladenburg raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $24 from $21 and keeps a Buy rating on the shares following the Q3 report. The firm increased its probability of sucess in soquelitinib’s peripheral T-cell lymphoma indication to 80%, viewing the chemotherapy arm as a relatively easy comparator.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer
- Corvus Pharmaceuticals Reports Q3 2024 Financial Results
- Corvus Pharmaceuticals reports Q3 EPS (60c), consensus (11c)
- Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings
- Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings